Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 12/20 | 1.00 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.51 |
| ▸ | PARP15 | Q460N3 | 4/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23635902 | 0.89 | STING1 (0.80) | STING1MCL1PARP15PARP10MAPK1 | |
| SCHEMBL23111988 | 0.88 | STING1 (0.79) | STING1MCL1PARP15MAPK1 | |
| SCHEMBL30765111 | 0.88 | STING1 (0.79) | STING1MCL1PARP15MAPK1 | |
| SCHEMBL23635897 | 0.88 | STING1 (0.78) | STING1MCL1PARP15PARP10MAPK1 | |
| SCHEMBL30697678 | 0.86 | STING1 (0.76) | STING1MCL1PARP15PARP10MAPK1 | |
| SCHEMBL23635813 | 0.86 | STING1 (0.76) | STING1MCL1PARP15PARP10MAPK1 | |
| SCHEMBL23630775 | 0.82 | STING1 (0.70) | STING1MCL1 | |
| SCHEMBL23630807 | 0.82 | STING1 (0.69) | STING1MCL1MAPK1 | |
| SCHEMBL23111974 | 0.81 | STING1 (0.68) | STING1MCL1PARP10MAPK1 | |
| SCHEMBL23630792 | 0.80 | STING1 (0.67) | STING1MCL1PARP15PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3793988-B1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2023-11-15 | — | — | EP | disclosed |
| EP-3793988-B1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2023-11-15 | — | — | EP | disclosed |
| US-20230227423-A1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2023-07-20 | — | — | US | disclosed |
| US-20230227423-A1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2023-07-20 | — | — | US | disclosed |
| US-20210214333-A1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | CTXT PTY LTD. (AU) | 2021-07-15 | — | — | US | disclosed |
| US-20210214333-A1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | CTXT PTY LTD. (AU) | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227423-A1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | STING1, CGAS, IRF3 | STING1 1/4885MCL1 1773/4885PARP15 3656/4885 |
| US-20210214333-A1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | STING1, CGAS, IRF3 | STING1 1/4885MCL1 1851/4885PARP15 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.